γ’/total fibrinogen ratio is associated with short-term outcome in ischaemic stroke

Summary

Fibrinogen γ’ (γ’) is a natural isoform of fibrinogen, and alters the rate of formation and the properties of clots. It could therefore affect outcome after ischaemic stroke. The prognostic significance of γ’ fibrinogen levels is, however, still unclear. It was the objective of this study to assess levels of γ’ in ischaemic stroke, and its association with short-term outcome. We included 200 ischaemic stroke patients and 156 control persons. Total fibrinogen and γ’ levels were measured; outcome at discharge was assessed by means of the modified Rankin Scale score (defined as unfavourable when >2). We compared levels between patients and controls using multiple linear regression analysis, and logistic regression analysis was used to assess the relationship between levels and outcome. All analyses were adjusted for age and sex. Mean γ’ levels were significantly higher in patients with ischaemic stroke than in controls (0.37 vs. 0.32 g/l, p<0.001), and patients also had a higher γ’/total fibrinogen ratio (0.102 vs. 0.096, p=0.19). The γ’/total fibrinogen ratio is associated with unfavourable outcome in patients with ischaemic stroke (odds ratio per unit increase of γ’/total fibrinogen ratio 1.27, 95% confidence interval 1.09–1.47). Our study shows that patients with ischaemic stroke have increased levels of fibrinogen γ’ and suggests a trend towards an increased γ’/total fibrinogen ratio in ischaemic stroke. Increased fibrinogen γ’ relative to total fibrinogen levels are associated with unfavourable outcome in the early phase after stroke.

Keywords

Ischaemic stroke - fibrinogen γ’ - outcome

• References

• 1 Cheung EY, Vos HL, Kruip MJ. et al. Elevated fibrinogen gamma’ ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome. Blood 2009; 114: 4603-4604.
• 2 Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (gamma’). Proc Natl Acad Sci USA 1980; 77: 5069-5073.
• 3 Wolfenstein-Todel C, Mosesson MW. Carboxy-terminal amino acid sequence of a human fibrinogen gamma-chain variant (gamma’). Biochemistry 1981; 20: 6146-6149.
• 4 Chung DW, Davie EW. Gamma and gamma’ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984; 23: 4232-4236.
• 5 Mosesson MW, Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89: 9-12.
• 6 Moaddel M, Farrell DH, Daugherty MA. et al. Interactions of human fibrinogens with factor XIII: roles of calcium and the gamma’ peptide. Biochemistry 2000; 39: 6698-6705.
• 7 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894-1904.
• 8 Cheung EY, Uitte de Willige S, Vos HL. et al. Fibrinogen gamma’ in ischemic stroke: a case-control study. Stroke 2008; 39: 1033-1035.
• 9 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ. et al. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma’ levels. Blood 2005; 106: 4176-4183.
• 10 Lovely RS, Falls LA, Al-Mondhiry HA. et al. Association of gammaA/gamma’ fibrinogen levels and coronary artery disease. Thromb Haemost 2002; 88: 26-31.
• 11 Mannila MN, Lovely RS, Kazmierczak SC. et al. Elevated plasma fibrinogen gamma’ concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007; 5: 766-773.
• 12 Nowak-Gottl U, Weiler H, Hernandez I. et al. Fibrinogen alpha and gamma genes and factor VLeiden in children with thromboembolism: results from 2 family-based association studies. Blood 2009; 114: 1947-1953.
• 13 Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 237-246.
• 14 Adams Jr. HP, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
• 15 van Swieten JC, Koudstaal PJ, Visser MC. et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607.
• 16 Dziedzic T. Clinical significance of acute phase reaction in stroke patients. Front Biosci 2008; 13: 2922-2927.
• 17 Uitte de Willige S, Standeven KF, Philippou H. et al. The pleiotropic role of the fibrinogen gamma’ chain in hemostasis. Blood 2009; 114: 3994-4001.
• 18 Gersh KC, Nagaswami C, Weisel JW, Lord ST. The presence of gamma’ chain impairs fibrin polymerization. Thromb Res 2009; 124: 356-363.
• 19 Cooper AV, Standeven KF, Ariens RA. Fibrinogen gamma-chain splice variant gamma’ alters fibrin formation and structure. Blood 2003; 102: 535-540.
• 20 Siebenlist KR, Mosesson MW, Hernandez I. et al. Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma’ chains. Blood 2005; 106: 2730-2736.
• 21 Falls LA, Farrell DH. Resistance of gammaA/gamma’ fibrin clots to fibrinolysis. J Biol Chem 1997; 272: 14251-1426.
• 22 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K. et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
• 23 Kofoed SC, Wittrup HH, Sillesen H. et al. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques: the Copenhagen City Heart Study. Eur Heart J 2003; 24: 567-576.
• 24 Danesh J, Collins R, Appleby P. et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc 1998; 279: 1477-1482.